This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The "Summary Page" provides a listing of product names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm377096.htm
The following drugs had modifications to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:
Prevpac (Lansoprazole 30 mg delayed-release, Amoxicillin 500 mg capsules and Clarithromycin 500 mg tablets)
Zestoretic (Lisinopril/Hydrochlorothiazide)
Zestril (Lisinopril)
Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide)
Aralen (Chloroquine Phosphate)
Jakafi (Ruxolitibib)
Lysodren (Mitotane)
Nexavar (Sorafenib)
Noxafil (Posaconazole)
Onfi (Clobazam)
Remicade (Infliximab)
Revlimid (Lenalidomide)
Simponi (Golimumab)
Tekamlo (Aliskiren and Amlodipine)
Tekturna (Aliskiren)
Tekturna HCT (Aliskiren and Hydrochlorothiazide)
Xalkori (Crizotinib)
![Alison Bryant, senior consultant at Antea Group and communications director for the Healthcare Plastics Recycling Council (HPRC), addressed the crowd at the[PACK]out.](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2024/05/Alison_Bryant.6644005a513b0.png?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
